Abstract
Thomas Novotny reflects on new research by Stanton Glantz and colleagues and the implications of their findings for engaging the tobacco industry on tobacco product regulation.
Highlights
Presentations to the Institute of Medicine (IOM) were carefully vetted by industry lawyers in order to protect the business of selling tobacco and to fend off meddlesome public health regulations over product development
In this week’s PLOS Medicine, Stanton Glantz and colleagues have conducted detailed historical research on the involvement of the tobacco industry, or at least its influence, in the preparation of an important Institute of Medicine (IOM) report (Clearing the Smoke) commissioned by the US Food and Drug Administration (FDA) in 2001 [1]
Presentations to the IOM were carefully vetted by industry lawyers in order to protect the business of selling tobacco and to fend off meddlesome public health regulations over product development
Summary
Presentations to the IOM were carefully vetted by industry lawyers in order to protect the business of selling tobacco and to fend off meddlesome public health regulations over product development. It was clear to the industry that tobacco regulation was going to Linked Research Article
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
